Sr Medical Scientist - US Medical Affairs - Oncology
The US Medical Affairs team at Amgen is looking for a medical monitor with oncology experience to support the execution of US Medical Affair studies.
Support the US medical leads in the planning, coordination and implementation of US medical (interventional and observational) studies
Serve as medical monitor for US Medical Affairs studies
Lead the cross-functional team in the development of protocol, protocol amendments, CRFs and research site educational resources
Support key external facing activities related to study conduct including site initiation visits, investigators meetings and steering committee meetings
Serve as the primary point of contact for protocol related inquiries
Support the clinical operations team in ensuring appropriate site selection, timely study start-up and execution of medical studies
Support database locks and data cleaning during the conduct of medical studies
Support the development of the clinical study report upon completion of medical studies
Assist sites with addressing IRB review inquiries
MD or DO degree from an accredited medical school
2 years of oncology clinical research experience
Clinical research/medical affairs experience in the biopharmaceutical industry (biotech, pharmaceutical or CRO)
Experience with clinical study management and conduct of oncology studies
Oncology disease expertise
Experience with opinion leader interactions
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.